JC10 Rec'd PCT/PTO 2 1 MAR 2005

FORM: PTO-1390 (Modified) U.S. PATENT AND TRADEMARK OFFICE; U.S. DEPARTMENT OF COMMERCE (REV. 12-2004)

## TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

CONCERNING A SUBMISSION UNDER 35 U.S.C. 371

P33118USW

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

10/528613

INTERNATIONAL APPLICATION NO. PCT/EP2003/010930

INTERNATIONAL FILING DATE **September 25, 2003** 

PRIORITY DATE CLAIMED September 27, 2002

TITLE OF INVENTION

Pyridine Derivatives As CB2 Receptor Modulators

APPLICANT	(S) FOR	DO/FO/US	;

		ГОN, Andrew, John; GIBLIN, Gerard, Martin, Paul; JANDU, Karamjit, Singh; MITCHELL, William, Leonaŕd;, , Alan; PALOMBI, Giovanni; RAWLINGS, Derek, Anthony; SLINGSBY, Brian, Peter; WHITTINGTON, Andrew, Richa					
Appli	cant h	erewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
1.	×	This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.					
2.		This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a submission under 35 U.S.C. 371.					
3.	Ü	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.					
4.	$\boxtimes$	The US has been elected (Article 31).					
5.	$\boxtimes$	A copy of the International Application as filed (35 U.S.C. 371 (c)(2))					
		a.  is attached hereto (required only if not communicated by the International Bureau).					
		b. 🗵 has been communicated by the International Bureau.					
		c.  is not required, as the application was filed in the United States Receiving Office (RO/US).					
6.							
		a. 🗋 is attached hereto.					
		b.  has been previously submitted under 35 U.S.C. 154(d)(4).					
7.	Ø	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))					
		a.   are attached hereto (required only if not communicated by the International Bureau).					
		b.  have been communicated by the International Bureau.					
-		c.  have not been made; however, the time limit for making such amendments has NOT expired.					
		d. 🖾 have not been made and will not be made.					
8.		An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).					
9.		An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).					
10.		An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).					
11.	$\boxtimes$	A copy of the International Preliminary Examination Report (PCT/IPEA/409).					
12.	$\boxtimes$	A copy of the International Search Report (PCT/ISA/210).					
Ite	ems 1	3 to 23 below concern document(s) or information included:					
13.	$\boxtimes$	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.					
14.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.					
15.	$\boxtimes$	A FIRST preliminary amendment.					
16.		A SECOND or SUBSEQUENT preliminary amendment.					
17.		A substitute specification.					
18.		A power of attorney and/or change of address letter.					
19.		A computer-readable form of the sequence-listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.					
20.		A second copy of the published International Application under 35 U.S.C. 154(d)(4).					
21.		A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).					
22.	$\boxtimes$	Express Mail Label No. EV 332064005 US					
23.	$\boxtimes$	Other items or information:					
_		a) PCT Cover Page b) PCT Request					

JC05 Rec'd PCT/PTO 21 MAR 2005

PTO-1390 (Rev. 12-2004)

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATIO	U.S. APPLICATION NO (if known, see 37 CFR 1.5) INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER						
	10/528613 PCT/EP2003/010930		0	P33118USW					
24. The following	•	id:				:	Applican		Office use
🖾 a) Basic nat	ional fee				• • •	\$300.00	\$	\$300.00	
•						\$200.00	\$	\$200.00	
🖾 c) Search fe	e					\$500.00	\$	\$500.00	
TOTA	AL OF ABOVE	CALCU	LATIONS =			\$1000.00	\$	\$1,000.00	
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.									
Total Sheets	Extra Sheets		r of each additional 50 c nereof (round <b>up</b> to a wh			RATE			
- 100 =	/50 =				x	\$250.00	\$	\$0.00	
	0.00 for furnishing priority date (37 Cl		r declaration later than n	nonth	s fron	n the	\$		
CLAIMS	NUMBER F	ILED	NUMBER EXTRA		RA1	ſΈ			
Total claims	17	- 20 =	0	х		\$50.00	\$	\$0.00	
Independent clair	ns 3	- 3=	0	х		\$200.00	\$	\$0.00	
MULTIPLE DEPE	ENDENT CLAIMS	(if applicabl	le)	+		\$360.00	\$	\$0.00	
		TO1	TAL OF ABOVE CA	LC	ULA	TIONS =	\$	\$1,000.00	l
☐ Applicant cla reduced by 1		atus. See 3	37 CFR 1.27. The fees in	ndica	ted at	ove are	\$	\$0.00	
SUBTOTAL =					<b>+</b>	\$	\$1,000.00		
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).					ths from	\$	\$0.00		
TOTAL NATIONAL FEE =				\$	\$1,000.00				
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +						\$	\$0.00		
TOTAL FEES ENCLOSED =				\$	\$1,000.00				
Amount to be refunded:						\$			
Amount to be charged:					charged:			\$	
a. A check	in the amount of \$		to cover the a	bove	fees i	is enclosed.	•		
	harge my Deposit ate copy of this she		o. <u>07-1392</u> ii	n the	amou	int of	\$1,000.00	to cove	r the above fees.
c. The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 07-1392 . A duplicate copy of this sheet is enclosed.									
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.									
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.									
SEND ALL CORRESPONDENCE TO:									
,				) `	$\searrow_{\hat{S}}$	IGNATURE			
23347 Lorie Ann				n Morgan					
				IAME					
38,181									
				)	R	EGISTRAT	ION NUMB	ER	

JC05 Rec'd PCT/PTO 21 MAR 2005

	MAILING BY "EXPRESS I	MAIL" (37 CFR 1.10)	Docket No.
Applicant(s): Eatherton	et al.		10 / BY 8 X 1 Z
Serial No.  To Be Assigned	Filing Date  Concurrently Herewith	Examiner	Group Art Unit
. Pyridine Der	ivatives As CB2 Receptor Modula	ators	
Invention: Fyridine Der			
I hereby certify that the	e following correspondence:		
Transmittal of Nationa	l Phase Application w/accompany	ing papers	
	(Identify type	of correspondence)	
-	n the United States Postal Service pe addressed to: Commissioner		
3	1) 21  05 (Date)	, , , , , , , , , , , , , , , , , , , ,	,
		Valerie L. Phi (Typed or Printed Name of Person M	illips
		Signature of Person Mailing	illim
		EV3320640	DSUS
•		-	· · · · · · · · · · · · · · · · · · ·